Fifty-seven cases of nephrotic syndrome were treated with TCM decoctions as accessory treatment for prednisone and cyclophosphamide, and the effects were observed in a follow-up period of 5-15 years. The long-term com...Fifty-seven cases of nephrotic syndrome were treated with TCM decoctions as accessory treatment for prednisone and cyclophosphamide, and the effects were observed in a follow-up period of 5-15 years. The long-term complete remission rate of 68.4% and recurrence rate of 26.3% in the treatment group were respectively higher and lower than those in the control group (P展开更多
BACKGROUND Target therapy is licensed by United States Food and Drug Administration on certain cancers.Both sorafenib and lenvatinib are tyrosine kinase inhibitor and indicated on radioactive iodine(RAI)-refractory di...BACKGROUND Target therapy is licensed by United States Food and Drug Administration on certain cancers.Both sorafenib and lenvatinib are tyrosine kinase inhibitor and indicated on radioactive iodine(RAI)-refractory differentiated thyroid cancer(DTC).Lenvatinib is more effective in cancers'control than sorafenib,but causes more nephrotoxicity than sorafenib does.This case is the second published case about the serial adaptions from lenvatinib to sorafenib for improving the proteinuria and,meanwhile,achieving the therapeutic goal.CASE SUMMARY A 56-year-old man suffered from bilateral edematous lower extremities after 1-mo prescription of lenvatinib of 20 mg/d for RAI-refractory DTC.Aside from this symptom,he also developed hypertension.His laboratory showed grade-3 proteinuria(estimated 24-h urine protein:9993 mg),hypoalbuminemia and hypercholesterolemia.Anti-vascular endothelial growth factor(VEGF)therapyinduced nephrotic syndrome was impressed.After reduced dosage of lenvatinib of 10 mg/d and related symptomatic drugs,limited improvement was observed in both adverse effects and caner control.Under this condition,we substituted sorafenib of 400 mg/d for lenvatinib of 10 mg/d.After a 5-mo prescription,not only hypertension and peripheral edema were greatly improved,but also proteinuria was improved from grade three to grade one(estimated 24-h urine protein:962 mg).At the same time the cancer control was achieved,judged from computed tomography and laboratory evidence[thyroglobulin(Tg)before prescription of sorafenib:354.7 ng/m L;Tg after prescription of sorafenib:108.9 ng/m L].CONCLUSION Adaption from lenvatinib to sorafenib is a feasible method to improve the antiVEGF therapy-induced nephrotic syndrome and achieve the therapeutic goal at the same time.展开更多
Fifty children with nephrotic syndrome were treated by using herbal drugs for nourishing yin to reduce pathogenic fire, strengthening qi and tonifying the kidney, and promoting blood circulation and removing blood... Fifty children with nephrotic syndrome were treated by using herbal drugs for nourishing yin to reduce pathogenic fire, strengthening qi and tonifying the kidney, and promoting blood circulation and removing blood stasis in combination with glucocorticoid and immunodepressant. The body height, secondary sex characters, age of the first spermatorrhea for male and of menarche for female children, bone age measured with roentgenograms on the left wrist in 50 cases of the treatment group were compared with those in 31 cases of the control group treated by glucocorticoid and immunodepressant. The results showed that the delay of growth and sexual development as side-effects of glucocorticoid and immunodepressant were markedly reduced by the integrated TCM-WM treatment.展开更多
【目的】系统评价益气养阴法联合西药治疗肾病综合征的有效性及安全性。【方法】检索中国知网(CNKI)、中国生物医学文献数据库(CBM)、万方(Wangfang)、维普(VIP)、PubMed、Web of Science、Cochrane Library、Embase等国内外主要文献数...【目的】系统评价益气养阴法联合西药治疗肾病综合征的有效性及安全性。【方法】检索中国知网(CNKI)、中国生物医学文献数据库(CBM)、万方(Wangfang)、维普(VIP)、PubMed、Web of Science、Cochrane Library、Embase等国内外主要文献数据库,筛选其中有关益气养阴法联合西药(试验组)对比单纯西药(对照组)治疗肾病综合征的临床随机对照试验(RCTs),采用Cochrane手册中的偏倚风险工具进行文献的质量评价,运用RevMan 5.3软件进行Meta分析。【结果】共纳入18个RCTs,包含1334例患者。Meta分析结果显示,益气养阴法联合西药在提高临床有效率(RR=1.24,95%CI[1.16,1.32],P<0.00001),改善24 h尿蛋白定量(24hUPRO)(MD=-0.92,95%CI[-1.09,-0.75],P<0.00001)、血清白蛋白(ALB)(MD=7.06,95%CI[4.73,9.39],P<0.00001)、尿素氮(BUN)(MD=-1.57,95%CI[-2.01,-1.13],P<0.00001)、血肌酐(SCr)(MD=-12.23,95%CI[-16.58,-7.88],P<0.00001)、总胆固醇(TC)(MD=-1.06,95%CI[-1.69,-0.43],P=0.0009)、甘油三酯(TG)(MD=-0.58,95%CI[-0.94,-0.21],P=0.002)水平,以及降低不良反应发生率(RR=0.50,95%CI[0.40,0.64],P<0.00001)方面优于单纯西药治疗。【结论】益气养阴法联合西药治疗肾病综合征在提高临床疗效及改善24hUPRO、ALB、BUN、SCr、TC、TG方面优于单纯西药治疗,且能降低激素产生的不良反应。因纳入文献较少,文献质量较低,潜在疗效需更多的高质量研究进行验证。展开更多
目的探讨罗沙司他联合基础疗法治疗原发性肾病综合征(PNS)继发急性肾损伤(AKI)患者的临床效果,以期为PNS继发AKI患者临床治疗方案的选择提供参考。方法选取2022年7月—2023年5月重庆大学附属中心医院收治的118例PNS继发AKI患者,采用随...目的探讨罗沙司他联合基础疗法治疗原发性肾病综合征(PNS)继发急性肾损伤(AKI)患者的临床效果,以期为PNS继发AKI患者临床治疗方案的选择提供参考。方法选取2022年7月—2023年5月重庆大学附属中心医院收治的118例PNS继发AKI患者,采用随机数字表法分为对照组和研究组,每组59例。对照组患者采用基础疗法治疗,研究组患者在对照组基础上联合罗沙司他治疗。比较2组患者的临床疗效,治疗前后的肾功能指标[血清肌酐(SCr)、尿素氮(BUN)、肾小球滤过率(eGFR)]、24 h尿蛋白定量(24 h Upro)、血浆白蛋白、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、血常规指标[白细胞计数(WBC)、红细胞计数(RBC)、血红蛋白(Hb)、血小板计数(PLT)]及肝功能指标[白蛋白(ALB)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)],并进行安全性评估。结果研究组患者的治疗总有效率为91.53%(54/59),高于对照组的77.97%(46/59),差异有统计学意义(χ^(2)=4.196,P=0.041)。2组患者不同治疗时间点的血清SCr、BUN水平及eGFR重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗7 d、14 d及28 d时的SCr、BUN水平均低于同一时间点的对照组,eGFR高于同一时间点的对照组,差异均有统计学意义(P<0.05)。2组患者不同治疗时间点的24 h Upro、血浆白蛋白、TC及TG水平重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗14 d及28 d时的24 h Upro、TC与TG水平均低于同一时间点的对照组,血浆白蛋白水平高于同一时间点的对照组(P<0.05);2组患者治疗前后LDL-C及HDL-C水平比较,差异无统计学意义(P>0.05)。2组患者治疗前及治疗28 d时的WBC、RBC、Hb、PLT、ALB、ALT、AST、TBIL水平比较,差异均无统计学意义(P>0.05)。研究组与对照组患者不良反应发生率分别为3.39%(2/59)和1.69%(1/59),差异无统计学意义(P>0.05)。结论罗沙司他联合基础疗法治疗PNS继发AKI患者的疗效确切,能有效改善患者肾功能与血脂代谢,具有较高的用药安全性,且对患者肝功能影响较小,值得在临床推广。展开更多
BACKGROUND Minimal change disease(MCD)is a significant cause of idiopathic nephrotic syndrome(INS)in adults,representing approximately 10%-15%of INS cases.The data is scanty on clinicopathological features,treatment r...BACKGROUND Minimal change disease(MCD)is a significant cause of idiopathic nephrotic syndrome(INS)in adults,representing approximately 10%-15%of INS cases.The data is scanty on clinicopathological features,treatment responses,and long-term outcomes of MCD in adults.AIM To determine the clinicopathologic characteristics,treatment responses,and medium-term outcomes of adult patients with MCD in Pakistan.METHODS This retrospective cohort study included all adult patients with biopsy-proven MCD treated at the adult nephrology clinic,Sindh institute of urology and transplantation,between January 2010 and December 2020.The data was retrieved from the original renal biopsy request forms in the histopathology archives and the case files.Data on demographics,clinical presentation,laboratory findings,treatment regimens,and outcomes were collected and analyzed.Complete remission(CR),partial remission(PR),relapse,and steroid resistance were defined according to standard criteria.Statistical analyses were performed using statistical product and service solutions,Version 22.RESULTS The study cohort included 23 adults[15(65.2%males),mean age 26.34±10.28 years].Hypertension was found in 7(30.4%)and microscopic hematuria in 10(43.4%)of participants.Laboratory findings revealed a mean serum creatinine of 1.03±1.00 mg/dL,mean serum albumin of 1.94±0.90 g/dL and mean 24-hour urinary proteins of 4.53±2.43 g.The mean follow-up time was 38.09±22.3 months.Treatment with steroids was effective in 16/18(88.8%)of patients,with 10/16(62.5%)achieving CR and 6/16(37.5%)achieving PR.Two patients were resistant to steroids and required second-line immunosuppressive therapy.Relapse occurred in 4/20(19.04%)of patients,with a mean time to first relapse of 6.5±3.31 months.At the last follow-up,18/20(85.7%)of patients were in remission,and 16/20(76.1%)maintained normal renal function.No patients progressed to end-stage renal disease or died.CONCLUSION MCD in adults shows a favorable response to steroid therapy,with a majority achieving remission.However,relapses are common,necessitating second-line immunosuppressive treatments in some cases.The study highlights the need for standardized treatment guidelines for adult MCD to optimize outcomes.展开更多
目的观察中药联合激素非拖尾疗法治疗儿童难治性肾病综合征(RNS)的临床疗效。方法将2019年6月至2022年6月在河南中医药大学第一附属医院门诊就诊的122例RNS患儿按照随机数字表法分为观察组(n=60)和对照组(n=62)。对照组给予泼尼松片联...目的观察中药联合激素非拖尾疗法治疗儿童难治性肾病综合征(RNS)的临床疗效。方法将2019年6月至2022年6月在河南中医药大学第一附属医院门诊就诊的122例RNS患儿按照随机数字表法分为观察组(n=60)和对照组(n=62)。对照组给予泼尼松片联合他克莫司治疗,其中泼尼松片治疗采用拖尾疗法,观察组在对照组基础上加用中药治疗(益气化瘀清热方序贯辨治),其中泼尼松片治疗采用非拖尾疗法。比较2组治疗前和治疗4周、12周、24周后24 h尿蛋白定量(24 h UTP)、血浆白蛋白(ALB)、血脂[总胆固醇(TC)、甘油三酯(TG)]的变化;比较治疗前和治疗24周后肝肾功能[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、血尿素氮(BUN)、血肌酐(SCr)]、中医证候积分和儿童RNS中医生存质量量表的变化;比较治疗52周后2组患儿激素总累积量、激素副作用、总有效率和复发率。结果2组患儿治疗4周、12周、24周后24 h UTP、ALB、TC、TG均较治疗前有改善,且观察组改善更明显(P<0.05,P<0.01);治疗24周后,2组患儿ALT、AST、BUN、SCr无明显变化(P>0.05),但中医证候积分均显著降低(P<0.05,P<0.01)、中医生存质量量表总积分显著增加(P<0.01),且观察组优于对照组(P<0.05,P<0.01);治疗52周后,观察组激素总累积量低于对照组(P<0.01)、激素副作用少于对照组(P<0.01)、总有效率高于对照组(P<0.05)、复发率低于对照组(P<0.05)。结论中药联合激素非拖尾疗法治疗儿童RNS能降低尿蛋白,升高血浆白蛋白,降低血脂,改善中医证候,提高生存质量,提高临床疗效。展开更多
文摘Fifty-seven cases of nephrotic syndrome were treated with TCM decoctions as accessory treatment for prednisone and cyclophosphamide, and the effects were observed in a follow-up period of 5-15 years. The long-term complete remission rate of 68.4% and recurrence rate of 26.3% in the treatment group were respectively higher and lower than those in the control group (P
文摘BACKGROUND Target therapy is licensed by United States Food and Drug Administration on certain cancers.Both sorafenib and lenvatinib are tyrosine kinase inhibitor and indicated on radioactive iodine(RAI)-refractory differentiated thyroid cancer(DTC).Lenvatinib is more effective in cancers'control than sorafenib,but causes more nephrotoxicity than sorafenib does.This case is the second published case about the serial adaptions from lenvatinib to sorafenib for improving the proteinuria and,meanwhile,achieving the therapeutic goal.CASE SUMMARY A 56-year-old man suffered from bilateral edematous lower extremities after 1-mo prescription of lenvatinib of 20 mg/d for RAI-refractory DTC.Aside from this symptom,he also developed hypertension.His laboratory showed grade-3 proteinuria(estimated 24-h urine protein:9993 mg),hypoalbuminemia and hypercholesterolemia.Anti-vascular endothelial growth factor(VEGF)therapyinduced nephrotic syndrome was impressed.After reduced dosage of lenvatinib of 10 mg/d and related symptomatic drugs,limited improvement was observed in both adverse effects and caner control.Under this condition,we substituted sorafenib of 400 mg/d for lenvatinib of 10 mg/d.After a 5-mo prescription,not only hypertension and peripheral edema were greatly improved,but also proteinuria was improved from grade three to grade one(estimated 24-h urine protein:962 mg).At the same time the cancer control was achieved,judged from computed tomography and laboratory evidence[thyroglobulin(Tg)before prescription of sorafenib:354.7 ng/m L;Tg after prescription of sorafenib:108.9 ng/m L].CONCLUSION Adaption from lenvatinib to sorafenib is a feasible method to improve the antiVEGF therapy-induced nephrotic syndrome and achieve the therapeutic goal at the same time.
文摘 Fifty children with nephrotic syndrome were treated by using herbal drugs for nourishing yin to reduce pathogenic fire, strengthening qi and tonifying the kidney, and promoting blood circulation and removing blood stasis in combination with glucocorticoid and immunodepressant. The body height, secondary sex characters, age of the first spermatorrhea for male and of menarche for female children, bone age measured with roentgenograms on the left wrist in 50 cases of the treatment group were compared with those in 31 cases of the control group treated by glucocorticoid and immunodepressant. The results showed that the delay of growth and sexual development as side-effects of glucocorticoid and immunodepressant were markedly reduced by the integrated TCM-WM treatment.
文摘目的探讨罗沙司他联合基础疗法治疗原发性肾病综合征(PNS)继发急性肾损伤(AKI)患者的临床效果,以期为PNS继发AKI患者临床治疗方案的选择提供参考。方法选取2022年7月—2023年5月重庆大学附属中心医院收治的118例PNS继发AKI患者,采用随机数字表法分为对照组和研究组,每组59例。对照组患者采用基础疗法治疗,研究组患者在对照组基础上联合罗沙司他治疗。比较2组患者的临床疗效,治疗前后的肾功能指标[血清肌酐(SCr)、尿素氮(BUN)、肾小球滤过率(eGFR)]、24 h尿蛋白定量(24 h Upro)、血浆白蛋白、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、血常规指标[白细胞计数(WBC)、红细胞计数(RBC)、血红蛋白(Hb)、血小板计数(PLT)]及肝功能指标[白蛋白(ALB)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)],并进行安全性评估。结果研究组患者的治疗总有效率为91.53%(54/59),高于对照组的77.97%(46/59),差异有统计学意义(χ^(2)=4.196,P=0.041)。2组患者不同治疗时间点的血清SCr、BUN水平及eGFR重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗7 d、14 d及28 d时的SCr、BUN水平均低于同一时间点的对照组,eGFR高于同一时间点的对照组,差异均有统计学意义(P<0.05)。2组患者不同治疗时间点的24 h Upro、血浆白蛋白、TC及TG水平重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗14 d及28 d时的24 h Upro、TC与TG水平均低于同一时间点的对照组,血浆白蛋白水平高于同一时间点的对照组(P<0.05);2组患者治疗前后LDL-C及HDL-C水平比较,差异无统计学意义(P>0.05)。2组患者治疗前及治疗28 d时的WBC、RBC、Hb、PLT、ALB、ALT、AST、TBIL水平比较,差异均无统计学意义(P>0.05)。研究组与对照组患者不良反应发生率分别为3.39%(2/59)和1.69%(1/59),差异无统计学意义(P>0.05)。结论罗沙司他联合基础疗法治疗PNS继发AKI患者的疗效确切,能有效改善患者肾功能与血脂代谢,具有较高的用药安全性,且对患者肝功能影响较小,值得在临床推广。
文摘BACKGROUND Minimal change disease(MCD)is a significant cause of idiopathic nephrotic syndrome(INS)in adults,representing approximately 10%-15%of INS cases.The data is scanty on clinicopathological features,treatment responses,and long-term outcomes of MCD in adults.AIM To determine the clinicopathologic characteristics,treatment responses,and medium-term outcomes of adult patients with MCD in Pakistan.METHODS This retrospective cohort study included all adult patients with biopsy-proven MCD treated at the adult nephrology clinic,Sindh institute of urology and transplantation,between January 2010 and December 2020.The data was retrieved from the original renal biopsy request forms in the histopathology archives and the case files.Data on demographics,clinical presentation,laboratory findings,treatment regimens,and outcomes were collected and analyzed.Complete remission(CR),partial remission(PR),relapse,and steroid resistance were defined according to standard criteria.Statistical analyses were performed using statistical product and service solutions,Version 22.RESULTS The study cohort included 23 adults[15(65.2%males),mean age 26.34±10.28 years].Hypertension was found in 7(30.4%)and microscopic hematuria in 10(43.4%)of participants.Laboratory findings revealed a mean serum creatinine of 1.03±1.00 mg/dL,mean serum albumin of 1.94±0.90 g/dL and mean 24-hour urinary proteins of 4.53±2.43 g.The mean follow-up time was 38.09±22.3 months.Treatment with steroids was effective in 16/18(88.8%)of patients,with 10/16(62.5%)achieving CR and 6/16(37.5%)achieving PR.Two patients were resistant to steroids and required second-line immunosuppressive therapy.Relapse occurred in 4/20(19.04%)of patients,with a mean time to first relapse of 6.5±3.31 months.At the last follow-up,18/20(85.7%)of patients were in remission,and 16/20(76.1%)maintained normal renal function.No patients progressed to end-stage renal disease or died.CONCLUSION MCD in adults shows a favorable response to steroid therapy,with a majority achieving remission.However,relapses are common,necessitating second-line immunosuppressive treatments in some cases.The study highlights the need for standardized treatment guidelines for adult MCD to optimize outcomes.
文摘目的观察中药联合激素非拖尾疗法治疗儿童难治性肾病综合征(RNS)的临床疗效。方法将2019年6月至2022年6月在河南中医药大学第一附属医院门诊就诊的122例RNS患儿按照随机数字表法分为观察组(n=60)和对照组(n=62)。对照组给予泼尼松片联合他克莫司治疗,其中泼尼松片治疗采用拖尾疗法,观察组在对照组基础上加用中药治疗(益气化瘀清热方序贯辨治),其中泼尼松片治疗采用非拖尾疗法。比较2组治疗前和治疗4周、12周、24周后24 h尿蛋白定量(24 h UTP)、血浆白蛋白(ALB)、血脂[总胆固醇(TC)、甘油三酯(TG)]的变化;比较治疗前和治疗24周后肝肾功能[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、血尿素氮(BUN)、血肌酐(SCr)]、中医证候积分和儿童RNS中医生存质量量表的变化;比较治疗52周后2组患儿激素总累积量、激素副作用、总有效率和复发率。结果2组患儿治疗4周、12周、24周后24 h UTP、ALB、TC、TG均较治疗前有改善,且观察组改善更明显(P<0.05,P<0.01);治疗24周后,2组患儿ALT、AST、BUN、SCr无明显变化(P>0.05),但中医证候积分均显著降低(P<0.05,P<0.01)、中医生存质量量表总积分显著增加(P<0.01),且观察组优于对照组(P<0.05,P<0.01);治疗52周后,观察组激素总累积量低于对照组(P<0.01)、激素副作用少于对照组(P<0.01)、总有效率高于对照组(P<0.05)、复发率低于对照组(P<0.05)。结论中药联合激素非拖尾疗法治疗儿童RNS能降低尿蛋白,升高血浆白蛋白,降低血脂,改善中医证候,提高生存质量,提高临床疗效。
